4B.03: EMPAGLIFLOZIN REDUCES SYSTOLIC BLOOD PRESSURE IN DIPPER AND NON-DIPPER PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION. (June 2015)

• Record Type: Journal Article
• Authors: Chilton, R.; Tikkanen, I.; Crowe, S.; Johansen, O.E.; Broedl, U.C.; Woerle, H.J.; Hach, T.
• Is Part Of: Journal of hypertension. Volume 33(2015)Supplement 1
• Publication Date: 2015-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000467487.05191.08
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: To assess changes in systolic blood pressure (SBP) with empagliflozin in patients with type 2 diabetes and hypertension (defined as mean seated office SBP 130–159 mmHg and diastolic BP 80–99 mmHg) categorised as dippers or non-dippers. Design and method: In a subgroup analysis of patients who received empagliflozin 10 mg, empagliflozin 25 mg or placebo in a Phase III randomised trial (EMPA-REG BP TM ), we assessed changes from baseline in SBP (mean 24-h, awake-time, sleep-time) via ambulatory BP monitoring at week 12 in patients categorised as dippers (sleep-time mean SBP <=90% of awake-time mean; n = 417) or non-dippers (sleep-time mean SBP > 90% of awake-time mean; n = 350). Results: Baseline mean (SD) 24-h SBP (mmHg) was 129.9 (11.6) in dippers and 133.1 (12.4) in non-dippers. Adjusted mean (SE) changes from baseline in mean 24-h SBP (mmHg) in dippers were -0.2 (0.7) with placebo versus -3.8 (0.6) and -3.9 (0.7) with empagliflozin 10 and 25 mg, respectively (both p < 0.001), and in non-dippers were 1.0 (0.7) with placebo versus -1.6 (0.7) with empagliflozin 10 mg (p = 0.013) and -3.8 (0.7) with empagliflozin 25 mg (p < 0.001). Hourly mean SBP patterns over 24 h for dippers and non-dippers were maintained with empagliflozin 10 mg and 25 mg. Compared with placebo, changes from baseline in awake-time and sleep-time SBP were significantly greater with empagliflozin 10 mg or 25 mg, except for sleep-time SBP with empagliflozin 10 mg. Conclusions: In patients with type 2 diabetes and hypertension, empagliflozin 10 mg and 25 mg significantly reduced SBP versus placebo in dippers and non-dippers.